Patent application number | Description | Published |
20110147672 | THIXOTROPIC CONDUCTIVE COMPOSITION - The presence of a rheology modifier in a conductive composition of metal coated core particles improves both rheology and conductivity. In preferred embodiments the rheology modifier is selected from the group consisting of fumed silica, carbon nano-tubes, and graphite. In further embodiments the metal coated particles are silver coated glass or copper particles. | 06-23-2011 |
20110210454 | Phase Separated Curable Compositions - A curable composition, suitable for underfill encapsulant, has two distinct phase domains after cure, a continuous phase and a discontinuous phase, in which one phase has a modulus value of 2 GPa or greater, and the second phase has a modulus value at least 1 Gpa less than the first phase, characterized in that the phases are generated in situ as the composition cures. | 09-01-2011 |
20130197158 | SELF-ALIGNED GRAPHENE POLYMER NANOCOMPOSITES - Highly-oriented graphene polymer nanocomposites are produced from an aqueous dispersion of graphene oxide in polyurethane latex followed by chemical reduction to form graphene sheets. | 08-01-2013 |
20140011904 | RADIATION CURABLE TEMPORARY LAMINATING ADHESIVE FOR USE IN HIGH TEMPERATURE APPLICATIONS - A radiation curable temporary laminating adhesive composition for use in temperature applications at 150° C. or greater, and typically at 200° C. or greater, comprises (A) a hydrogenated polybutadiene diacrylate; (B) a radical photoinitiator; and (C) a diluent. | 01-09-2014 |
20140174801 | CONDUCTIVE MATERIAL AND PROCESS - A conductive ink comprises nanosilver particles, and adhesion promoters, in which no binders, such as polymers or resins, are used in the compositions. In one embodiment the adhesion promoters are oxydianiline and 4,4-(1,3-phenylenedioxy)dianiline. | 06-26-2014 |
20140178601 | CONDUCTIVE MATERIAL AND PROCESS - A method for making a conductive network of sintered silver comprises preparing a conductive ink comprising a silver compound and a binder; depositing the conductive ink on a substrate and applying an external energy source to the deposited conductive ink to dry the ink; and applying an external energy source to the dried ink to decompose the ink to elemental silver and to sinter the elemental silver into a conductive network. | 06-26-2014 |
20140209951 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF - Oxetane-containing compounds, and compositions of oxetane-containing compounds together with carboxylic acids, latent carboxylic acids, and/or compounds having carboxylic acid and latent carboxylic acid functionality are provided. The oxetane-containing compounds and compositions thereof are useful as adhesives, sealants and encapsulants, particularly for components, and in the assembly, of LED devices. | 07-31-2014 |
20140295066 | ELECTROLESS PLATING OF SILVER ONTO GRAPHITE - A one-pot process for the electroless-plating of silver onto graphite powder is disclosed. No powder pretreatment steps for the graphite, which typically require filtration, washing or rinsing, are required. The inventive process comprises mixing together three reactant compositions in water: an aqueous graphite activation composition comprising graphite powder and a functional silane, a silver-plating composition comprising a silver salt and a silver complexing agent, and a reducing agent composition. | 10-02-2014 |
20150322276 | FLEXIBLE CONDUCTIVE INK - This invention is a flexible conductive ink composition comprising (A) a resin binder, (B) silver-plated core conductive particles, and (C) conductive particles having a surface area at least 1.0 m | 11-12-2015 |
Patent application number | Description | Published |
20100190759 | NK 1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 07-29-2010 |
20100227873 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula (I): | 09-09-2010 |
20110098468 | NK1 ANTAGONISTS | 04-28-2011 |
20110207734 | Azine Derivatives and Methods of Use Thereof - The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 08-25-2011 |
20110243940 | BICYCLIC PYRANONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Bicyclic Pyranone Derivatives, their compositions and uses for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. Formula (I). Y is —C— when an optional and additional bond is present and Y is —CH— when an optional and additional bond is not present; Z is —O—, —NH— or —N(alkyl)- when the optional and additional bond between Y and Z Is absent, and Z Is —N— when the optional and additional bond between Y and Z is present; R | 10-06-2011 |
20110245209 | PYRIDOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyridopyrimidine Derivatives of formula (I), compositions comprising a Pyridopyrimidine Derivative and methods for using the Pyridopyrimidine Derivatives for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. | 10-06-2011 |
20110245267 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel Piperidine and piperazine Derivatives, pharmaceutical compositions comprising the Piperidine and piperazine Derivatives and the use of these compounds of formula (I) for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 10-06-2011 |
20120295879 | NK1 Antagonists - A compound having the general structure shown in Formula I: | 11-22-2012 |
20120316154 | FUSED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X | 12-13-2012 |
20130023503 | NK1 ANTAGONISTS | 01-24-2013 |
20130210805 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS - This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH | 08-15-2013 |
20130303517 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J | 11-14-2013 |
20140213571 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 07-31-2014 |
20140296196 | NK1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 10-02-2014 |
20140336158 | NK1 ANTAGONISTS | 11-13-2014 |
20150361098 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES - Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. | 12-17-2015 |
20150361101 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 12-17-2015 |
20150368246 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I | 12-24-2015 |
20150368265 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I | 12-24-2015 |
20160002255 | ANTIDIABETIC BICYCLIC COMPOUNDS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 01-07-2016 |
20160130259 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 05-12-2016 |
20160136172 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 05-19-2016 |
Patent application number | Description | Published |
20080263221 | SYSTEM AND METHOD FOR STORE-AND-FORWARD FOR HIGHLY AVAILABLE MESSAGE PRODUCTION - The present invention enables a store-and-forward service that provides higher availability for application residing or connecting to a server to reliably deliver messages and allows an application to send messages to a destination on another server even when the destination is not available at the moment the messages are sent because of network problems or system failures. The messages will be stored durably and temporarily on a local server, and then be efficiently forwarded to the destination once it becomes available. | 10-23-2008 |
20090259715 | SYSTEM AND METHOD FOR CLIENT INTEROPERABILITY - Disclosed herein is a system and method for client interoperability. In one embodiment, a method for client interoperability comprises establishing a network connection between a client and a proxy. The client requests a connection factory from the proxy. The proxy then obtains the connection factory from an application server using a Java Naming and Directory Interface (JNDI). Using the connection factory, a connection to a connection host from the client is created. When the client sends a message, the proxy receives the message and routes the message to a destination server. Similarly, when the client receives a message, the proxy receives the message from a destination server and passes the message to the client. The client can be specifically configured to extend JMS operability to a desired language. In one embodiment the client is a .NET client. | 10-15-2009 |
20130290425 | METHOD FOR A CONNECTOR PROVIDING TRANSACTIONAL INTEROPERABILITY TO MULTIPLE MESSAGING PROVIDERS TO MULTIPLE APPLICATION SERVERS USING THE SAME IMPLEMENTATION - A system includes a resource adapter module in the form of executable code by a processor, the resource adapter module to, interact with an application running on an application server by receiving calls from applications, and provide communication between the application and any JMS provider by relaying the calls to the JMS provider. | 10-31-2013 |
20130290524 | SYSTEM AND METHOD FOR CLUSTERED TRANSACTIONAL INTEROPERABILITY OF MULTIPLE MESSAGING PROVIDERS USING A SINGLE CONNECTOR MECHANISM - A system has at least one requesting application residing upon a requesting application server, a cluster of processing message servers, a resource adapter in the form of executable code being executed by a processor on a first computer, the resource adapter to receive a request from the requesting application; transmit the request to the cluster of processing message servers; monitor processing of the request on the cluster of processing message servers; handling any exception in the processing of the request; and responding to the requesting application when the processing is complete. The system also includes an interposed transaction manager in the form of executable code being executed by a processor, the interposed transaction manager to receive transactional operations associated with the requests, and providing transaction guarantees related to the transactional operations. | 10-31-2013 |
20130290983 | SYSTEM AND METHOD FOR CLUSTERED TRANSACTIONAL INTEROPERABILITY OF PROPRIETARY NON-STANDARD FEATURES OF A MESSAGING PROVIDER USING A CONNECTOR MECHANISM - A computer-controlled method of handling proprietary features in a messaging system includes receiving an object from a requesting application, determining that the object invokes proprietary features of a messaging system, accessing a wrapper library and wrapping the object in an appropriate wrapper for the messaging system to produce a wrapped object, the wrapper to preserve the proprietary feature, and transmitting the wrapped object to the messaging system. | 10-31-2013 |
20160070494 | HIGHLY PERFORMANT RELIABLE MESSAGE STORAGE USING IN-MEMORY REPLICATION TECHNOLOGY - A system and method can provide a scalable data storage in a middleware environment. The system can include a cluster of replicated store daemon processes in a plurality of processing nodes, wherein each machine node can host a replicated store daemon process of the cluster of replicated store daemon processes. Additionally, the system can include one or more replicated stores associated with an application server the processing node. The replicated store daemon cluster can persist data from a replicated store to another node, the other node also being associated with the replicated store daemon cluster. The system and method can additionally support a messaging service in a middleware environment. The messaging service can use the replicated store to store a copy of a message in the local processing node and on another processing node associated with the same replicated store daemon cluster. | 03-10-2016 |
20160094405 | SYSTEM AND METHOD FOR MULTITENANCY STORE IN A MULTITENANT APPLICATION SERVER ENVIRONMENT - In accordance with an embodiment, a system and method provides a messaging service in a multitenant application server environment. Deployable resources are usable within the multitenant environment and groupings of resources are defined by resource group templates within a domain. One or more partitions are provided, each partition providing an administrative and runtime subdivision of the domain that can be associated with a tenant. Java message service (JMS) resources are defined within a resource group template or a resource group, and instantiated within a partition to enable messaging for applications deployed within the partition and between partitions. Integrating JMS in a multitenant application server environment further includes a custom store defined within each of the resource group templates for use by the JMS resources. Components of the custom store are fully partition scoped and exist in an isolated JNDI name-space and use fully partition scoped runtime MBeans and configuration MBeans. | 03-31-2016 |
20160094498 | SYSTEM AND METHOD FOR JMS INTEGRATION IN A MULTITENANT APPLICATION SERVER ENVIRONMENT - In accordance with an embodiment, a system and method provides a messaging service in a multitenant application server environment. Deployable resources are usable within the multitenant application server environment and groupings of resources are defined by resource group templates within a domain. One or more partitions are provided, with each partition providing an administrative and runtime subdivision of the domain that can be associated with a tenant. Java message service (JMS) resources are defined within a resource group template or a resource group, and instantiated within a partition to enable messaging for applications deployed within the partition and between partitions. Integrating JMS in a multitenant application server environment further includes a foreign JMS server feature which maps remotely hosted JMS connection factories and JMS destinations into a local partition's JNDI, so that bridges and applications in turn gain access to these resources by looking them up in this name-space. | 03-31-2016 |
20160094510 | SYSTEM AND METHOD FOR MESSAGING IN A MULTITENANT APPLICATION SERVER ENVIRONMENT - In accordance with an embodiment, a system and method provides a messaging service in a multitenant application server environment. Deployable resources are usable within the multitenant application server environment and groupings of resources are defined by resource group templates within a domain. One or more partitions are provided, with each partition providing an administrative and runtime subdivision of the domain that can be associated with a tenant. Java message service (JMS) resources are defined within a resource group template or a resource group, and instantiated within a partition from the one or more partitions to enable messaging for applications deployed within the partition and between the one or more partition. | 03-31-2016 |
Patent application number | Description | Published |
20100075961 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR | 03-25-2010 |
20100076014 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds. | 03-25-2010 |
20100113532 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): | 05-06-2010 |
20100190820 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (R | 07-29-2010 |
20120214767 | TRICYCLIC HETEROCYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 08-23-2012 |
20140235591 | BICYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 08-21-2014 |
20150191483 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS - Described are RORγ modulators of the formula (I), | 07-09-2015 |
20150315128 | BICYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 11-05-2015 |
20160052888 | SUBSTITUTED BICYCLIC COMPOUNDS - Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): | 02-25-2016 |
Patent application number | Description | Published |
20080310737 | EXEMPLAR-BASED HETEROGENEOUS COMPOSITIONAL METHOD FOR OBJECT CLASSIFICATION - A method for automatically generating a strong classifier for determining whether at least one object is detected in at least one image is disclosed, comprising the steps of: (a) receiving a data set of training images having positive images; (b) randomly selecting a subset of positive images from the training images to create a set of candidate exemplars, wherein said positive images include at least one object of the same type as the object to be detected; (c) training a weak classifier based on at least one of the candidate exemplars, said training being based on at least one comparison of a plurality of heterogeneous compositional features located in the at least one image and corresponding heterogeneous compositional features in the one of set of candidate exemplars; (d) repeating steps (c) for each of the remaining candidate exemplars; and (e) combining the individual classifiers into a strong classifier, wherein the strong classifier is configured to determine the presence or absence in an image of the object to be detected. | 12-18-2008 |
20090153661 | METHOD FOR BUILDING AND EXTRACTING ENTITY NETWORKS FROM VIDEO - A computer implemented method for deriving an attribute entity network (AEN) from video data is disclosed, comprising the steps of: extracting at least two entities from the video data; tracking the trajectories of the at least two entities to form at least two tracks; deriving at least one association between at least two entities by detecting at least one event involving the at least two entities, said detecting of at least one event being based on detecting at least one spatio-temporal motion correlation between the at least two entities; and constructing the AEN by creating a graph wherein the at least two objects form at least two nodes and the at least one association forms a link between the at least two nodes. | 06-18-2009 |
20090316983 | Real-Time Action Detection and Classification - The present invention relates to a method and system for creating a strong classifier based on motion patterns wherein the strong classifier may be used to determine an action being performed by a body in motion. When creating the strong classifier, action classification is performed by measuring similarities between features within motion patterns. Embodiments of the present invention may utilize candidate part-based action sets and training samples to train one or more weak classifiers that are then used to create a strong classifier. | 12-24-2009 |
20100202657 | SYSTEM AND METHOD FOR OBJECT DETECTION FROM A MOVING PLATFORM - The present invention relates to a system and method for detecting one or more targets belonging to a first class (e.g., moving and/or stationary people), from a moving platform in a 3D-rich environment. The framework described here is implemented using a number of monocular or stereo cameras distributed around the vehicle to provide 360 degrees coverage. Furthermore, the framework described here utilizes numerous filters to reduce the number of false positive identifications of the targets. | 08-12-2010 |
20120321137 | METHOD FOR BUILDING AND EXTRACTING ENTITY NETWORKS FROM VIDEO - A computer implemented method for deriving an attribute entity network (AEN) from video data is disclosed, comprising the steps of: extracting at least two entities from the video data; tracking the trajectories of the at least two entities to form at least two tracks; deriving at least one association between at least two entities by detecting at least one event involving the at least two entities, said detecting of at least one event being based on detecting at least one spatio-temporal motion correlation between the at least two entities; and constructing the AEN by creating a graph wherein the at least two objects form at least two nodes and the at least one association forms a link between the at least two nodes. | 12-20-2012 |
Patent application number | Description | Published |
20100247569 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 09-30-2010 |
20140044745 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 02-13-2014 |
20140308307 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 10-16-2014 |
20150093405 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 04-02-2015 |
Patent application number | Description | Published |
20090112004 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS - The present invention is directed to a process, having a reduced environmental impact, for preparing phenylamino substituted quaternary salt compounds that are CCR2 antagonists. | 04-30-2009 |
20100004450 | Process for the preparation of substituted pyrimidine derivatives - The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H | 01-07-2010 |
20100029942 | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives - The present invention is directed to benzoimidazol-2-yl pyrimidine derivatives useful as histamine H | 02-04-2010 |
20100197689 | NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES - The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides, useful for the treatment of disorders and conditions mediated by the histamine receptor. | 08-05-2010 |
20100286391 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES - The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor. | 11-11-2010 |
20120029191 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES - The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor. | 02-02-2012 |
20120178932 | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatgives - The present invention is directed to benzoimidazol-2-yl pyrimidine derivatives useful as histamine H | 07-12-2012 |
20120184740 | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives - The present invention is directed to benzoimidazol-2-yl pyrimidine derivatives useful as histamine H | 07-19-2012 |
20120283433 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES - The present invention is directed to novel processes for the preparation of cyclopropyl-amide derivatives, useful for the treatment of disorders and conditions mediated by the histamine receptor. | 11-08-2012 |
20130053561 | Process for the preparation of substituted pyrimidine derivatives - The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H | 02-28-2013 |
20130225816 | Process for the preparation of substituted pyrimidine derivatives - The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H | 08-29-2013 |
20130303552 | NOVEL INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS - Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient. | 11-14-2013 |
20140066624 | Process for the preparation of substituted pyrimidine derivatives - The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H | 03-06-2014 |
20140073795 | Process for the preparation of substituted pyrimidine derivatives - The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H | 03-13-2014 |
20150087659 | NOVEL INHIBITORS OF SECRETION OF HEPATITIS B VIRUS ANTIGENS - Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient. | 03-26-2015 |
20160024004 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION - The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections. | 01-28-2016 |